deltatrials
Completed PHASE1 NCT00098332

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

A Phase I, Multi-Center, Open-Label, Safety and Pharmacokinetic, Repeat-Dose Study of Oral Forodesine Hydrochloride in Patients With Refractory Cutaneous T-Cell Lymphoma

Sponsor: BioCryst Pharmaceuticals

Conditions Lymphoma
Interventions forodesine hydrochloride
Updated 5 times since 2017 Last updated: Jul 9, 2013 Started: Nov 30, 2004 Primary completion: Dec 31, 2010 Completion: Jul 31, 2011

A PHASE1 clinical study on Lymphoma, this trial is completed. The trial is conducted by BioCryst Pharmaceuticals and has accumulated 5 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BioCryst Pharmaceuticals
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Aurora, United States
  • • Birmingham, United States
  • • Boston, United States
  • • Cincinnati, United States
  • • Durham, United States
  • • Hot Springs, United States
  • • Houston, United States
  • • Lecanto, United States
  • • New Haven, United States
  • • Stanford, United States